Home › Kidney Cancer › Illinois › Waukegan
Kidney Cancer clinical trials in Waukegan, IL
3 studies for Kidney Cancer are looking for participants at sites in and around Waukegan (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RecruitingPhase 1
- NEO-811 Chicago Site, Zion · 6 mi away
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
RecruitingPhase 3
- Research Site, Zion · 6 mi away
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- City Of Hope - Chicago, Zion · 6 mi away
About Kidney Cancer
Kidney cancer symptoms are hard to detect at first but they do exist. Read more about the top 5 symptoms and the treatment options available
More about Kidney Cancer on MedlinePlus
Kidney Cancer trials in other cities
- New York City, NY15 studies
- Boston, MA12 studies
- Nashville, TN12 studies
- Houston, TX10 studies
- San Diego, CA9 studies
- St. Louis, MO9 studies
- Dallas, TX9 studies
- Washington, DC9 studies
- Seattle, WA8 studies
- Edison, NJ8 studies
- Miami, FL8 studies
- Los Angeles, CA7 studies
Other studies in Waukegan
- Non-Small Cell Lung Cancer16 studies
- Lung Cancer16 studies
- Breast Cancer12 studies
- Ulcerative Colitis7 studies
- Kidney Cancer (Renal Cell Carcinoma)7 studies
- Ovarian Cancer6 studies
- Metastatic Cancer6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Colorectal Cancer6 studies
- Prostate Cancer6 studies
- Melanoma5 studies
- Acute Myeloid Leukemia5 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.